Invention Grant
- Patent Title: BAFF selective binding compounds and related methods
-
Application No.: US16547221Application Date: 2019-08-21
-
Publication No.: US11267894B2Publication Date: 2022-03-08
- Inventor: Julien Häsler , Julia Lynn Rutkowski
- Applicant: Ossianix, Inc.
- Applicant Address: US PA Philadelphia
- Assignee: Ossianix, Inc.
- Current Assignee: Ossianix, Inc.
- Current Assignee Address: US PA Philadelphia
- Agency: Kacvinsky Daisak Bluni PLLC
- Main IPC: C07K16/28
- IPC: C07K16/28 ; C07K16/24 ; A61K39/395 ; A61K47/68 ; G01N33/68 ; C07K14/525 ; C07K14/705 ; C07K14/71 ; A61K39/00

Abstract:
The present invention relates to peptide antagonists that bind with high specificity and affinity to B-Lymphocyte stimulator (“BAFF”), thereby antagonizing BAFF receptor (“BAFF-R”) signaling. The invention more specifically relates to VNAR single chain antibodies derived from nurse shark that bind to BAFF, BAFF antagonist compounds and compositions comprising a BAFF specific VNAR binding moiety, methods for preparing them, diagnostic and therapeutic methods of use relating to in vitro or in vivo B cell depletion, e.g., to treat and/or prevent a pathological condition, disorder or disease in which it is beneficial to kill or deplete B cells, such as in autoimmune diseases including systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) or multiple sclerosis (MS), and in certain hematological cancers, including lymphomas, leukemias and myelomas.
Public/Granted literature
- US20200024354A1 BAFF SELECTIVE BINDING COMPOUNDS AND RELATED METHODS Public/Granted day:2020-01-23
Information query